Assenagon Asset Management S.A. Has $4.25 Million Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Assenagon Asset Management S.A. cut its position in AtriCure, Inc. (NASDAQ:ATRC) by 39.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,101 shares of the medical device company’s stock after selling 90,029 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.29% of AtriCure worth $4,251,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Canada Pension Plan Investment Board grew its position in AtriCure by 187.7% in the 2nd quarter. Canada Pension Plan Investment Board now owns 110,669 shares of the medical device company’s stock worth $2,520,000 after purchasing an additional 72,200 shares during the last quarter. State Street Corp grew its position in AtriCure by 4.9% in the 3rd quarter. State Street Corp now owns 1,344,856 shares of the medical device company’s stock worth $37,710,000 after purchasing an additional 63,002 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of AtriCure by 2.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,152,628 shares of the medical device company’s stock worth $32,326,000 after acquiring an additional 32,676 shares during the period. Atom Investors LP bought a new position in shares of AtriCure during the 3rd quarter worth about $1,741,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of AtriCure by 12.8% during the 2nd quarter. Renaissance Technologies LLC now owns 171,700 shares of the medical device company’s stock worth $3,910,000 after acquiring an additional 19,500 shares during the period. 99.11% of the stock is currently owned by institutional investors and hedge funds.

AtriCure Trading Up 2.2 %

ATRC opened at $38.47 on Tuesday. The company has a current ratio of 3.62, a quick ratio of 2.59 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $1.88 billion, a PE ratio of -46.35 and a beta of 1.42. AtriCure, Inc. has a 1-year low of $18.94 and a 1-year high of $39.12. The firm has a 50-day moving average price of $33.84 and a two-hundred day moving average price of $29.15.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Tuesday, October 29th. The medical device company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.02. AtriCure had a negative net margin of 8.70% and a negative return on equity of 8.12%. The company had revenue of $115.91 million during the quarter, compared to analysts’ expectations of $112.23 million. During the same quarter in the previous year, the company earned ($0.20) EPS. AtriCure’s revenue was up 17.9% on a year-over-year basis. As a group, equities analysts anticipate that AtriCure, Inc. will post -0.73 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ATRC has been the subject of a number of analyst reports. Canaccord Genuity Group raised their price objective on shares of AtriCure from $53.00 to $61.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Oppenheimer raised their price objective on shares of AtriCure from $32.00 to $36.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. reissued an “overweight” rating and set a $40.00 price target on shares of AtriCure in a report on Tuesday, December 17th. UBS Group lifted their price target on shares of AtriCure from $35.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, Needham & Company LLC reissued a “buy” rating and set a $40.00 price target on shares of AtriCure in a report on Monday, January 13th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $42.00.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.